Personalising myeloma care – insights from the RADAR trial
Published:
This approach gives UK patients with the highest risk of relapsing early (within 18 months of treatment) the opportunity to receive more intensive treatments not currently available through the NHS, to help improve remission times. By tailoring treatment to patient-specific risk profiles, clinicians could optimise patient care, reduce the risk of early relapse, and increase life expectancy.
Sign up and become a member of the Myeloma UK HCP Hub
Access exclusive content like this and join in the conversation.
Already have an account?